Imperial College London
Portrait Picture

DrMelpomeniKalofonou

Faculty of Engineering, Department of Electrical and Electronic Engineering

Research Fellow in Cancer Technology
 
 
 
//

Contact

 

+44 (0)20 7594 1594m.kalofonou Website CV

 
 
//

Location

 

B420C - Centre for Bio-Inspired Technology (CBIT)Bessemer BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Wormald:2022:10.1038/s41598-022-12557-y,
author = {Wormald, BW and Moser, N and deSouza, NM and Mantikas, K-T and Malpartida-Cardenas, K and Pennisi, I and Ind, TEJ and Vroobel, K and Kalofonou, M and Rodriguez-Manzano, J and Georgiou, P},
doi = {10.1038/s41598-022-12557-y},
journal = {Scientific Reports},
title = {Lab-on-Chip assay of tumour markers and Human Papilloma Virus for cervical cancer detection at the point-of-care},
url = {http://dx.doi.org/10.1038/s41598-022-12557-y},
volume = {12},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cervical cancer affects over half a million people worldwide each year, the majority of whom are in resource-limited settingswhere cytology screening is not available. As persistent human papilloma virus (HPV) infections are a key causative factor,detection of HPV strains now complements cytology where screening services exist. This work demonstrates the efficacy ofa handheld Lab-on-Chip (LoC) device, with an external sample extraction process, in detecting cervical cancer from biopsysamples. The device is based on Ion-Sensitive Field-Effect Transistor (ISFET) sensors used in combination with loop-mediatedisothermal amplification (LAMP) assays, to amplify HPV DNA and human telomerase reverse transcriptase (hTERT) mRNA.These markers were selected because of their high levels of expression in cervical cancer cells, but low to nil expression innormal cervical tissue. The achieved analytical sensitivity for the molecular targets resolved down to a single copy per reactionfor the mRNA markers, achieving a limit of detection of 102for hTERT. In the tissue samples, HPV-16 DNA was present in 4/5malignant and 2/5 benign tissues, with HPV-18 DNA being present in 1/5 malignant and 1/5 benign tissues. hTERT mRNA wasdetected in all malignant and no benign tissues, with the demonstrated pilot data to indicate the potential for using the LoC incervical cancer screening in resource-limited settings on a large scale.
AU  - Wormald,BW
AU  - Moser,N
AU  - deSouza,NM
AU  - Mantikas,K-T
AU  - Malpartida-Cardenas,K
AU  - Pennisi,I
AU  - Ind,TEJ
AU  - Vroobel,K
AU  - Kalofonou,M
AU  - Rodriguez-Manzano,J
AU  - Georgiou,P
DO  - 10.1038/s41598-022-12557-y
PY  - 2022///
SN  - 2045-2322
TI  - Lab-on-Chip assay of tumour markers and Human Papilloma Virus for cervical cancer detection at the point-of-care
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-022-12557-y
UR  - https://www.nature.com/articles/s41598-022-12557-y.pdf
UR  - http://hdl.handle.net/10044/1/96953
VL  - 12
ER  -
Download